| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NRD2308 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/nrd2308 |
| P698 | PubMed publication ID | 17541420 |
| P5875 | ResearchGate publication ID | 6295749 |
| P50 | author | Ghislain Opdenakker | Q37065855 |
| Philippe E Van den Steen | Q42369206 | ||
| P2093 | author name string | Jialiang Hu | |
| Qing-Xiang A Sang | |||
| P2860 | cites work | Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis | Q80002082 |
| Medial collateral ligament healing in macrophage metalloelastase (MMP-12)-deficient mice | Q80201774 | ||
| Cold preservation of isolated sinusoidal endothelial cells in MMP 9 knockout mice: effect on morphology and platelet adhesion | Q80610463 | ||
| Impaired immunity to intestinal bacterial infection in stromelysin-1 (matrix metalloproteinase-3)-deficient mice | Q80833094 | ||
| Role of matrix metalloproteinase-9 in endothelial apoptosis in chronic heart failure in mice | Q81008508 | ||
| Matrix metalloproteinase-9 modulation by resident arterial cells is responsible for injury-induced accelerated atherosclerotic plaque development in apolipoprotein E-deficient mice | Q81475505 | ||
| Inhibition of obliterative airway disease development in murine tracheal allografts by matrix metalloproteinase-9 deficiency | Q81507537 | ||
| Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front | Q81562221 | ||
| Surfactant protein-D regulates soluble CD14 through matrix metalloproteinase-12 | Q81621923 | ||
| Hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor and erythropoietin in the absence of matrix metalloproteinase-9 | Q81875550 | ||
| Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice | Q82928035 | ||
| The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family | Q24557562 | ||
| Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms | Q24623052 | ||
| MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes | Q24628843 | ||
| Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand | Q24644662 | ||
| Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization | Q24646424 | ||
| Inflammation and cancer | Q24649640 | ||
| Macrophage metalloelastase (MMP-12) deficiency does not alter bleomycin-induced pulmonary fibrosis in mice | Q25256719 | ||
| Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed | Q27618464 | ||
| X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design | Q27730217 | ||
| Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor | Q27731527 | ||
| Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3 | Q28144040 | ||
| Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense | Q28145389 | ||
| Molecular Recognition of Protein−Ligand Complexes: Applications to Drug Design | Q28202151 | ||
| Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9) | Q28204521 | ||
| Design and therapeutic application of matrix metalloproteinase inhibitors | Q28212260 | ||
| Gelatinase B deficiency protects against endotoxin shock | Q28220536 | ||
| Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin | Q28395498 | ||
| Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice | Q28588786 | ||
| Galectin-3 is a downstream regulator of matrix metalloproteinase-9 function during endochondral bone formation | Q28595005 | ||
| The ADAMTS metalloproteinases | Q29544428 | ||
| Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations | Q29544430 | ||
| New functions for the matrix metalloproteinases in cancer progression | Q29547738 | ||
| The pathophysiology and treatment of sepsis | Q29619103 | ||
| The immunopathogenesis of sepsis | Q29622909 | ||
| Selection of a histidine-containing inhibitor of gelatinases through deconvolution of combinatorial tetrapeptide libraries | Q42803020 | ||
| Suppression of adjuvant arthritis of rats by a novel matrix metalloproteinase-inhibitor | Q43264390 | ||
| Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat | Q43558010 | ||
| Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis | Q43719854 | ||
| A combination of a chemically modified doxycycline and a bisphosphonate synergistically inhibits endotoxin-induced periodontal breakdown in rats | Q43721782 | ||
| Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy | Q43786938 | ||
| A murine model of toluene diisocyanate-induced asthma can be treated with matrix metalloproteinase inhibitor | Q43821994 | ||
| Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis | Q43903188 | ||
| Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis | Q44002202 | ||
| Design and synthesis of novel inhibitors of gelatinase B. | Q44071209 | ||
| Gelatinase B is diabetogenic in acute and chronic pancreatitis by cleaving insulin. | Q44355278 | ||
| Matrix Metalloproteinases Inhibition Attenuates Tobacco Smoke-Induced Emphysema in Guinea Pigs | Q44436336 | ||
| Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation | Q44448903 | ||
| Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. | Q44601270 | ||
| Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment o | Q44725424 | ||
| Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody | Q44855768 | ||
| Matrix metalloproteinase-9 deficiency impairs host defense mechanisms against Streptococcus pneumoniae in a mouse model of bacterial meningitis | Q44882363 | ||
| Doxycycline reduces airway inflammation and hyperresponsiveness in a murine model of toluene diisocyanate-induced asthma | Q44886971 | ||
| Generation of glycosylated remnant epitopes from human collagen type II by gelatinase B. | Q45018699 | ||
| The expression of matrix metalloproteinase-12 by oligodendrocytes regulates their maturation and morphological differentiation. | Q45041113 | ||
| Gelatinase B/matrix metalloproteinase-9 contributes to cellular infiltration in a murine model of zymosan peritonitis | Q45092937 | ||
| Matrix metalloproteinase-9 deficiency impairs host defense against abdominal sepsis | Q45131662 | ||
| Mmp-9 deficiency enhances collagenase-induced intracerebral hemorrhage and brain injury in mutant mice | Q45141100 | ||
| In vivo activation of gelatinase B/MMP-9 by trypsin in acute pancreatitis is a permissive factor in streptozotocin-induced diabetes | Q45147489 | ||
| Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice | Q45240483 | ||
| Matrix metalloproteinase 9 facilitates collagen remodeling and angiogenesis for vascular constructs | Q45288039 | ||
| Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth | Q45873353 | ||
| Formation of the dentino-enamel interface in enamelysin (MMP-20)-deficient mouse incisors | Q46281901 | ||
| Retinal vascular development and pathologic retinal angiogenesis are not impaired in matrix metalloproteinase-2 deficient mice | Q46432753 | ||
| Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. | Q46576483 | ||
| The brain-specific tissue-type plasminogen activator inhibitor, neuroserpin, protects neurons against excitotoxicity both in vitro and in vivo | Q46739636 | ||
| Myocardial ischemia induces interleukin-6 and tissue factor production in patients with coronary artery disease: a dobutamine stress echocardiography study | Q46802784 | ||
| An Adverse Role for Matrix Metalloproteinase 12 after Spinal Cord Injury in Mice | Q47400562 | ||
| Regulation by C5a of neutrophil activation during sepsis | Q47672797 | ||
| Impaired alveolization in mice deficient in membrane-type matrix metalloproteinase 1 (MT1-MMP). | Q47729507 | ||
| Matrix metalloproteinase-8 deficiency promotes granulocytic allergen-induced airway inflammation | Q47752298 | ||
| Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy | Q47891881 | ||
| The effect of adjunctive low-dose doxycycline therapy on clinical parameters and gingival crevicular fluid matrix metalloproteinase-8 levels in chronic periodontitis | Q47941807 | ||
| Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer | Q47976225 | ||
| Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. | Q48468454 | ||
| Role of matrix metalloproteinases in delayed cortical responses after stroke. | Q48604373 | ||
| Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. | Q48640163 | ||
| Matrix metalloproteinase-9-mediated dendritic cell recruitment into the airways is a critical step in a mouse model of asthma. | Q49027198 | ||
| Resistance of collagenase-2 (matrix metalloproteinase-8)-deficient mice to TNF-induced lethal hepatitis. | Q49099417 | ||
| Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. | Q49133201 | ||
| Selective ablation of matrix metalloproteinase-2 exacerbates experimental colitis: contrasting role of gelatinases in the pathogenesis of colitis. | Q50077344 | ||
| Transforming growth factor (TGF)-beta1 stimulates pulmonary fibrosis and inflammation via a Bax-dependent, bid-activated pathway that involves matrix metalloproteinase-12. | Q50232161 | ||
| Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae. | Q50495245 | ||
| Delayed inflammation-associated corneal neovascularization in MMP-2-deficient mice. | Q51549098 | ||
| The involvement of matrix metalloproteinases in basement membrane injury in a murine model of acute allergic airway inflammation. | Q51701514 | ||
| Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. | Q51786158 | ||
| Tumor targeting with a selective gelatinase inhibitor | Q30747366 | ||
| MMP-2 and MMP-9 synergize in promoting choroidal neovascularization | Q31013160 | ||
| Corneal neovascularization after excimer keratectomy wounds in matrilysin-deficient mice | Q31123069 | ||
| Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2-deficient mice. | Q31123109 | ||
| Absence of mechanical allodynia and Abeta-fiber sprouting after sciatic nerve injury in mice lacking membrane-type 5 matrix metalloproteinase | Q33197078 | ||
| Simulation of evolution-selected propeptide by high-throughput selection of a peptidomimetic inhibitor on a capillary DNA sequencer platform. | Q33213420 | ||
| Inhibition of lethal endotoxin shock with an L-pyridylalanine containing metalloproteinase inhibitor selected by high-throughput screening of a new peptide library | Q33259227 | ||
| Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency | Q33622543 | ||
| Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. | Q33665742 | ||
| Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans | Q34028910 | ||
| Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases | Q34092968 | ||
| Inhibition of autoimmune encephalomyelitis by a tetracycline. | Q34113359 | ||
| Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus | Q34212891 | ||
| Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. | Q34226948 | ||
| Metalloproteinases in biology and pathology of the nervous system. | Q34297141 | ||
| Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment | Q34302655 | ||
| Elastin fragments drive disease progression in a murine model of emphysema | Q34338306 | ||
| Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice | Q34346225 | ||
| Toll-like receptors: how they work and what they do. | Q34468201 | ||
| Strategies for MMP inhibition in cancer: innovations for the post-trial era. | Q34810420 | ||
| Neutralizing antibodies in gene-defective hosts | Q35053404 | ||
| Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye | Q35083557 | ||
| New frontiers in cardiology: drug-eluting stents: Part II. | Q35125882 | ||
| Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis | Q35592638 | ||
| Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). | Q35634821 | ||
| Matrix metalloproteinases promote inflammation and fibrosis in asbestos-induced lung injury in mice | Q35676548 | ||
| Matrix metalloproteinase-9 deficiency impairs cellular infiltration and bronchial hyperresponsiveness during allergen-induced airway inflammation | Q35747617 | ||
| Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer. | Q35779496 | ||
| Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium | Q35791414 | ||
| Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases | Q35824305 | ||
| The role of metalloelastase in immune complex-induced acute lung injury. | Q35842301 | ||
| Matrix metalloproteinases as modulators of inflammation and innate immunity | Q35852281 | ||
| Chemically modified tetracyclines as inhibitors of matrix metalloproteinases | Q35856969 | ||
| The countercurrent principle in invasion and metastasis of cancer cells. Recent insights on the roles of chemokines. | Q35878919 | ||
| Matrix metalloproteinases (MMPs) in oral diseases. | Q35943087 | ||
| Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results | Q36050642 | ||
| Crystal structures of MMPs in complex with physiological and pharmacological inhibitors | Q36076479 | ||
| Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and pathological significance | Q36107510 | ||
| Matrix metalloproteinases and free radicals in cerebral ischemia | Q36144616 | ||
| Metalloproteinases: mediators of pathology and regeneration in the CNS. | Q36313201 | ||
| Vascular remodeling and protease inhibition--bench to bedside | Q36357530 | ||
| What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models? | Q36373670 | ||
| Matrix metalloproteinase deficiencies affect contact hypersensitivity: stromelysin-1 deficiency prevents the response and gelatinase B deficiency prolongs the response | Q36384927 | ||
| Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid | Q36401533 | ||
| Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases | Q36447419 | ||
| Novel functions of TIMPs in cell signaling | Q36471132 | ||
| The immune response in atherosclerosis: a double-edged sword | Q36508676 | ||
| Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. | Q36580334 | ||
| A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window | Q36678875 | ||
| Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice | Q36799271 | ||
| Proteomic identification of in vivo substrates for matrix metalloproteinases 2 and 9 reveals a mechanism for resolution of inflammation | Q36967346 | ||
| Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury | Q37138010 | ||
| Matrix metalloproteinase-3-dependent generation of a macrophage chemoattractant in a model of herniated disc resorption | Q37174699 | ||
| MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. | Q37370581 | ||
| Matrilysin expression and function in airway epithelium | Q37385157 | ||
| Altered endochondral bone development in matrix metalloproteinase 13-deficient mice | Q37407318 | ||
| Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines | Q37407320 | ||
| Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice | Q38584976 | ||
| Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling | Q39735936 | ||
| Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms | Q39738340 | ||
| A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains | Q40264843 | ||
| Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells | Q40277201 | ||
| Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. | Q40340860 | ||
| The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. | Q40434427 | ||
| Reduced retinal angiogenesis in MMP-2-deficient mice | Q40547231 | ||
| Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption | Q40716553 | ||
| Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. | Q40857787 | ||
| Matrix metalloproteinase inhibitors in the treatment of cancer | Q40901330 | ||
| Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice | Q41051040 | ||
| The molecular basis of leukocytosis | Q41759585 | ||
| Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor | Q41839052 | ||
| Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis | Q41895463 | ||
| Enamelysin (matrix metalloproteinase 20)-deficient mice display an amelogenesis imperfecta phenotype. | Q52113450 | ||
| Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. | Q52507299 | ||
| Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. | Q52548108 | ||
| The metalloproteinase MT1-MMP is required for normal development and maintenance of osteocyte processes in bone. | Q52561730 | ||
| MMP-12 has a role in abdominal aortic aneurysms in mice. | Q52563459 | ||
| Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. | Q53348981 | ||
| Membrane-type 1 matrix metalloproteinase is required for normal alveolar development. | Q53625816 | ||
| Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. | Q53659623 | ||
| Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. | Q53662097 | ||
| Time-dependent changes in myocardial structure following discrete injury in mice deficient of matrix metalloproteinase-3. | Q53676019 | ||
| Different roles for matrix metalloproteinase-2 and matrix metalloproteinase-9 in the pathogenesis of cardiac allograft rejection. | Q53688825 | ||
| The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. | Q54035460 | ||
| Inhibition of alveolar bone loss by matrix metalloproteinase inhibitors in experimental periodontal disease. | Q54550703 | ||
| The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. | Q54585384 | ||
| An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization. | Q54650311 | ||
| Earlier Onset of Tumoral Angiogenesis in Matrix Metalloproteinase-19–Deficient Mice | Q57082637 | ||
| Role of matrix metalloproteinase-9 in a mouse model for amyotrophic lateral sclerosis | Q57244961 | ||
| Prevention of acute autoimmune encephalomyelitis and abrogation of relapses in murine models of multiple sclerosis by the protease inhibitor D-penicillamine | Q57247191 | ||
| Enhanced early vascular permeability in gelatinase B (MMP-9)-deficient mice: putative contribution of COX-1-derived PGE2 of macrophage origin | Q57584340 | ||
| Matrix metalloproteinase-9 (gelatinase B) deficiency leads to increased severity of Staphylococcus aureus-triggered septic arthritis | Q57584350 | ||
| Targeting neutrophil collagenase/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock | Q57584404 | ||
| Structural Characterization of the Catalytic Active Site in the Latent and Active Natural Gelatinase B from Human Neutrophils | Q57584591 | ||
| Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases | Q57584769 | ||
| The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis | Q59276652 | ||
| The influence of transforming growth factor beta 1 on the expression of genes coding for matrix metalloproteinases and tissue inhibitors of metalloproteinases during regeneration from cerulein-induced pancreatitis | Q60609544 | ||
| Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure | Q62383757 | ||
| Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action | Q70176370 | ||
| Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790 | Q70951168 | ||
| Preclinical antiarthritic activity of matrix metalloproteinase inhibitors | Q72853061 | ||
| Tissue inhibitor of matrix metalloproteinases-1 impairs arterial neointima formation after vascular injury in mice | Q73254517 | ||
| Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation | Q73257355 | ||
| Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor | Q73270598 | ||
| Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNF alpha processing | Q73556798 | ||
| Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits | Q73589806 | ||
| X-ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to a highly selective mechanism-based inhibitor. comparison with the latent and active forms of the enzyme | Q73694165 | ||
| Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice | Q73709481 | ||
| Role of stromelysin 1 and gelatinase B in experimental acute lung injury | Q73877425 | ||
| Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction | Q74060223 | ||
| Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation | Q74514976 | ||
| Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production | Q74583501 | ||
| The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis | Q74650599 | ||
| Matrix metalloproteinase-9 deficiency results in enhanced allergen-induced airway inflammation | Q75424883 | ||
| Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors | Q77744501 | ||
| The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases | Q77744504 | ||
| Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases | Q77795461 | ||
| Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin | Q77995830 | ||
| Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury | Q78460679 | ||
| Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release | Q78773775 | ||
| Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan | Q79346630 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 480-498 | |
| P577 | publication date | 2007-06-01 | |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases | |
| P478 | volume | 6 |
| Q33484792 | "Reverse degradomics", monitoring of proteolytic trimming by multi-CE and confocal detection of fluorescent substrates and reaction products |
| Q50002216 | 4-Thiazolidinone Derivatives as MMP Inhibitors in Tissue Damage: Synthesis, Biological Evaluation and Docking Studies. |
| Q48324984 | A DNA-directed covalent conjugation fluorescence probe for in vitro detection of functional matrix metalloproteinases. |
| Q36370996 | A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions |
| Q30430629 | A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications |
| Q33680972 | A macrophage cell model for selective metalloproteinase inhibitor design |
| Q42824423 | A matrix metalloproteinase 1-cleavable composite peptide derived from transforming growth factor β-inducible gene h3 potently inhibits collagen-induced arthritis |
| Q38647716 | A new gallium complex inhibits tumor cell invasion and matrix metalloproteinase MMP-14 expression and activity |
| Q33912089 | A novel chemically modified curcumin reduces severity of experimental periodontal disease in rats: initial observations |
| Q36977451 | A novel non-antibacterial, non-chelating hydroxypyrazoline derivative of minocycline inhibits nociception and oedema in mice. |
| Q36791078 | ADAM17 Inhibitors Attenuate Corneal Epithelial Detachment Induced by Mustard Exposure. |
| Q41002103 | ADAMTS-7 promotes vascular smooth muscle cells proliferation in vitro and in vivo |
| Q38292405 | AMPK Activation by Metformin Suppresses Abnormal Extracellular Matrix Remodeling in Adipose Tissue and Ameliorates Insulin Resistance in Obesity |
| Q36222825 | Active-site MMP-selective antibody inhibitors discovered from convex paratope synthetic libraries |
| Q35239944 | Adult vascular wall resident multipotent vascular stem cells, matrix metalloproteinases, and arterial aneurysms |
| Q38014072 | Advances in studies on collagenase inhibitors |
| Q34297175 | Altered circulating levels of matrix metalloproteinases and inhibitors associated with elevated type 2 cytokines in lymphatic filarial disease |
| Q33615432 | Altered serum level of cartilage oligomeric matrix protein and its association with coronary calcification in patients with coronary heart disease |
| Q50103980 | An integrated structure- and pharmacophore-based MMP-12 virtual screening. |
| Q34187459 | Applications of chitin and its derivatives in biological medicine |
| Q55110275 | Association of serum ADAMTS-7 levels with left ventricular reverse remodeling after ST-elevation myocardial infarction. |
| Q37332258 | Attacking the multi-tiered proteolytic pathology of COPD: new insights from basic and translational studies |
| Q37949641 | Bacterial meningitis: current therapy and possible future treatment options |
| Q51055833 | Biochemical and Biological Attributes of Matrix Metalloproteinases. |
| Q28288148 | Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade |
| Q37619125 | Bioresponsive nanosensors in medical imaging |
| Q27010013 | Blood-brain barrier breakdown in acute and chronic cerebrovascular disease |
| Q36834901 | Bone biology-related gingival transcriptome in ageing and periodontitis in non-human primates |
| Q34336586 | Bone marrow-derived matrix metalloproteinase-9 is associated with fibrous adhesion formation after murine flexor tendon injury |
| Q33622449 | Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice |
| Q91762795 | Cardiac remodeling secondary to chronic volume overload is attenuated by a novel MMP9/2 blocking antibody |
| Q41138570 | Cardiosome mediated regulation of MMP9 in diabetic heart: role of mir29b and mir455 in exercise |
| Q64099958 | Cellular and Molecular Effects of High-Molecular-Weight Heparin on Matrix Metalloproteinase 9 Expression |
| Q38941483 | Challenges to develop novel anti-inflammatory and analgesic drugs |
| Q36369055 | Changes in Oxidative Stress and Inflammatory Biomarkers in Fragile Adults over Fifty Years of Age and in Elderly People Exclusively Fed Enteral Nutrition |
| Q37632925 | Chemical biology for understanding matrix metalloproteinase function |
| Q35447969 | Circular trimers of gelatinase B/matrix metalloproteinase-9 constitute a distinct population of functional enzyme molecules differentially regulated by tissue inhibitor of metalloproteinases-1. |
| Q84945086 | Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction |
| Q34009507 | Cloning and expression of ADAM-related metalloproteases in equine laminitis |
| Q38888495 | Cognitive dysfunction in Duchenne muscular dystrophy: a possible role for neuromodulatory immune molecules. |
| Q50881896 | Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages. |
| Q34360507 | Comparison of the Effects of Matrix Metalloproteinase Inhibitors on TNF-α Release from Activated Microglia and TNF-α Converting Enzyme Activity |
| Q57584107 | Comparisons of gut microbiota profiles in wild-type and gelatinase B/matrix metalloproteinase-9-deficient mice in acute DSS-induced colitis |
| Q34592776 | Compromised NK cell-mediated antibody-dependent cellular cytotoxicity in chronic SIV/SHIV infection |
| Q51097569 | Computational Approaches to Matrix Metalloprotease Drug Design. |
| Q35876551 | Concentration kinetics of serum MMP-9 and TIMP-1 after blunt multiple injuries in the early posttraumatic period |
| Q42696941 | Crucial role of HSP90 in the Akt-dependent promotion of angiogenic-like effect of glucose-regulated protein94 (Grp94)-IgG complexes. |
| Q27321544 | DIDS prevents ischemic membrane degradation in cultured hippocampal neurons by inhibiting matrix metalloproteinase release |
| Q33986501 | Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-α converting enzyme (TACE/ADAM-17). |
| Q56986479 | Design, Synthesis, and Biological Evaluation of Tetrahydro-β-carboline Derivatives as Selective Sub-Nanomolar Gelatinase Inhibitors |
| Q90207975 | Developing an Antibody-Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein |
| Q36258684 | Differential Expression of Matrix Metalloproteinases 2, 9 and Cytokines by Neutrophils and Monocytes in the Clinical Forms of Chagas Disease. |
| Q36331820 | Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: A comparative study |
| Q34202064 | Differential spatio-temporal regulation of MMPs in the 5xFAD mouse model of Alzheimer's disease: evidence for a pro-amyloidogenic role of MT1-MMP. |
| Q36644315 | Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. |
| Q38495057 | Drugging the schistosome zinc-dependent HDACs: current progress and future perspectives |
| Q36556350 | Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine |
| Q38355876 | Effect of cold ischemia/reperfusion injury and/or shear stress with portal hypertension on the expression of matrix metalloproteinase-9. |
| Q37689496 | Effect of subcutaneous treatment with human umbilical cord blood-derived multipotent stem cells on peripheral neuropathic pain in rats |
| Q55031807 | Effects of Vitamin D3 on the NADPH Oxidase and Matrix Metalloproteinase 9 in an Animal Model of Global Cerebral Ischemia. |
| Q33568669 | Effects of detergents on catalytic activity of human endometase/matrilysin 2, a putative cancer biomarker |
| Q37031268 | Effects of ectopic expression of NGAL on doxorubicin sensitivity |
| Q33715912 | Effects of novel semiselective matrix metalloproteinase inhibitors on ex vivo cardiac structure-function |
| Q35389391 | Elevated levels of active matrix metalloproteinase-9 cause hypertrophy in skeletal muscle of normal and dystrophin-deficient mdx mice. |
| Q34282102 | Emerging principles in protease-based drug discovery |
| Q28242435 | Emerging targets in neuroinflammation-driven chronic pain |
| Q28073947 | Endothelial Response to Glucocorticoids in Inflammatory Diseases |
| Q42368319 | Endotoxemia shifts neutrophils with TIMP-free gelatinase B/MMP-9 from bone marrow to the periphery and induces systematic upregulation of TIMP-1. |
| Q36194829 | Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia |
| Q98772259 | Epithelial cell-specific loss of function of Miz1 causes a spontaneous COPD-like phenotype and up-regulates Ace2 expression in mice |
| Q34912678 | Evaluating prodrug strategies for esterase-triggered release of alcohols |
| Q42056130 | Evaluation of 11 scoring functions performance on matrix metalloproteinases |
| Q42144131 | Evidence for a Proapoptotic Role of Matrix Metalloproteinase-26 in Human Prostate Cancer Cells and Tissues |
| Q89944633 | Expression of MMP-2, MMP-9, and NGAL in Tissue and Serum of Patients with Vascular Aneurysms and Their Modulation by Statin Treatment: A Pilot Study |
| Q33694487 | Extracellular matrix molecules: potential targets in pharmacotherapy. |
| Q37939732 | Extracellular proteolysis in macrophage migration: losing grip for a breakthrough |
| Q35086168 | FRET-based and other fluorescent proteinase probes. |
| Q48543248 | Fell‐Muir Lecture: Metalloproteinases: from demolition squad to master regulators |
| Q36078299 | Fragment-Based Discovery of 5-Arylisatin-Based Inhibitors of Matrix Metalloproteinases 2 and 13. |
| Q39645443 | Free energy calculations on snake venom metalloproteinase BaP1. |
| Q26779933 | Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases |
| Q60951598 | Galangin Inhibits Thrombin-Induced MMP-9 Expression in SK-N-SH Cells via Protein Kinase-Dependent NF-κB Phosphorylation |
| Q33887938 | Gelatin degradation assay reveals MMP-9 inhibitors and function of O-glycosylated domain |
| Q24568374 | Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression |
| Q59136611 | Gelatinase B/Matrix Metalloproteinase-9 as Innate Immune Effector Molecule in Achalasia |
| Q57061847 | Gelatinase B/matrix metalloproteinase-9 is a phase-specific effector molecule, independent from Fas, in experimental autoimmune encephalomyelitis |
| Q37193691 | Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy |
| Q46757984 | Gingival crevicular fluid and serum matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 levels in renal transplant patients undergoing different immunosuppressive therapy |
| Q37353175 | Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis |
| Q26745510 | Glycosylation of matrix metalloproteases and tissue inhibitors: present state, challenges and opportunities |
| Q41048068 | Grafting MAP peptide to dental polymer inhibits MMP-8 activity |
| Q52900205 | Hemorrhagic metalloproteinase, Cc HSM-III, isolated from Cerastes cerastes venom: Purification and biochemical characterization. |
| Q27316480 | Hepatoprotective effect of MMP-19 deficiency in a mouse model of chronic liver fibrosis |
| Q37595298 | Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants. |
| Q38182192 | Host matrix metalloproteinases in cerebral malaria: new kids on the block against blood-brain barrier integrity? |
| Q38350129 | Human rhinovirus infection up-regulates MMP-9 production in airway epithelial cells via NF-{kappa}B. |
| Q27311200 | Hydrophilic extract from Posidonia oceanica inhibits activity and expression of gelatinases and prevents HT1080 human fibrosarcoma cell line invasion |
| Q38014073 | Hydroxamic acids as matrix metalloproteinase inhibitors |
| Q33806982 | IL-6 and high glucose synergistically upregulate MMP-1 expression by U937 mononuclear phagocytes via ERK1/2 and JNK pathways and c-Jun |
| Q35635079 | Identification of matrix metalloproteinase inhibitors by chemical arrays |
| Q48434563 | Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier. |
| Q37564195 | Impaired activity-dependent neural circuit assembly and refinement in autism spectrum disorder genetic models |
| Q51017366 | In silico study combining docking and QSAR methods on a series of matrix metalloproteinase 13 inhibitors. |
| Q34175711 | Including receptor flexibility and induced fit effects into the design of MMP-2 inhibitors |
| Q36990163 | Incorporation of Bulky and Cationic Cyclam-Triazole Moieties into Marimastat Can Generate Potent MMP Inhibitory Activity without Inducing Cytotoxicity |
| Q44195273 | Increased cyclooxygenase activity impairs apoptosis of inflammatory neutrophils in mice lacking gelatinase B/matrix metalloproteinase-9. |
| Q36618438 | Increased matrix metalloproteinase (MMPs) levels do not predict disease severity or progression in emphysema |
| Q84110434 | Increased serum levels of matrix metalloproteinase-9 in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation |
| Q57265309 | Infliximab Restores the Dysfunctional Matrix Remodeling Protein and Growth Factor Gene Expression in Patients with Inflammatory Bowel Disease |
| Q42571243 | Inhibition of MMP-9-dependent Degradation of Gelatin, but Not Other MMP-9 Substrates, by the MMP-9 Hemopexin Domain Blades 1 and 4. |
| Q43253807 | Inhibition of enzymatic degradation of adhesive-dentin interfaces |
| Q37171756 | Inhibition of matrix metalloproteinases enhances in vitro repair of the meniscus |
| Q34696039 | Inhibition of neutrophil collagenase/MMP-8 and gelatinase B/MMP-9 and protection against endotoxin shock. |
| Q42726346 | Inhibitor of PI3Kγ ameliorates TNBS-induced colitis in mice by affecting the functional activity of CD4+CD25+FoxP3+ regulatory T cells |
| Q28547985 | Inhibitory Effect of Aqueous Extracts from Marine Sponges on the Activity and Expression of Gelatinases A (MMP-2) and B (MMP-9) in Rat Astrocyte Cultures |
| Q28477370 | Insights into the complex formed by matrix metalloproteinase-2 and alloxan inhibitors: molecular dynamics simulations and free energy calculations |
| Q27313841 | Insufficiently defined genetic background confounds phenotypes in transgenic studies as exemplified by malaria infection in Tlr9 knockout mice |
| Q40112560 | Integrative studies implicate matrix metalloproteinase-12 as a culprit gene for large-artery atherosclerotic stroke |
| Q39080263 | Interplay of extracellular matrix and leukocytes in lung inflammation. |
| Q53173976 | Intracellular Wnt/Beta-Catenin Signaling Underlying 17beta-Estradiol-Induced Matrix Metalloproteinase 9 Expression in Human Endometriosis. |
| Q37456901 | Intracellular regulation of matrix metalloproteinase-2 activity: new strategies in treatment and protection of heart subjected to oxidative stress |
| Q37784801 | Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. |
| Q26744390 | Involvement of matrix metalloproteinases (MMPs) and inflammasome pathway in molecular mechanisms of fibrosis |
| Q38265674 | Is there new hope for therapeutic matrix metalloproteinase inhibition? |
| Q44086832 | Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3. |
| Q36943114 | Keratinocyte expression of MMP3 enhances differentiation and prevents tumor establishment |
| Q36395757 | Ligand-induced expansion of the S1' site in the anthrax toxin lethal factor |
| Q92443818 | Lipopolysaccharide-Induced Matrix Metalloproteinase-9 Expression Associated with Cell Migration in Rat Brain Astrocytes |
| Q37866602 | Lung cancer in pulmonary fibrosis: tales of epithelial cell plasticity |
| Q41176062 | MMP-12 catalytic domain recognizes triple helical peptide models of collagen V with exosites and high activity |
| Q41099760 | MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study. |
| Q33340257 | MMP19 is essential for T cell development and T cell-mediated cutaneous immune responses |
| Q33727374 | Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. |
| Q92502869 | Matrix Metalloproteases as Influencers of the Cells' Social Media |
| Q40464605 | Matrix Metalloproteinase 1 Causes Vasoconstriction and Enhances Vessel Reactivity to Angiotensin II via Protease-Activated Receptor 1. |
| Q50916304 | Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders. |
| Q91644631 | Matrix Metalloproteinase Triple-Helical Peptide Inhibitors: Potential Cross-Reactivity with Caspase-11 |
| Q92479030 | Matrix Metalloproteinase in Abdominal Aortic Aneurysm and Aortic Dissection |
| Q36088748 | Matrix Metalloproteinase-1 and Matrix Metalloproteinase-9 in the Aqueous Humor of Diabetic Macular Edema Patients. |
| Q27678085 | Matrix Metalloproteinase-10 (MMP-10) Interaction with Tissue Inhibitors of Metalloproteinases TIMP-1 and TIMP-2: BINDING STUDIES AND CRYSTAL STRUCTURE |
| Q41908742 | Matrix Metalloproteinase-9 and Haemozoin: Wedding Rings for Human Host and Plasmodium falciparum Parasite in Complicated Malaria |
| Q36316444 | Matrix Metalloproteinases as Regulators of Vein Structure and Function: Implications in Chronic Venous Disease |
| Q51055817 | Matrix Metalloproteinases in Remodeling of Lower Extremity Veins and Chronic Venous Disease. |
| Q47223491 | Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease |
| Q43100620 | Matrix metalloprotease regulation of neuropathic pain |
| Q34138756 | Matrix metalloproteinase 9 opposes diet-induced muscle insulin resistance in mice |
| Q34667430 | Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research |
| Q38431602 | Matrix metalloproteinase collagenolysis in health and disease |
| Q37983293 | Matrix metalloproteinase inhibition therapy for vascular diseases |
| Q33947243 | Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice |
| Q37253560 | Matrix metalloproteinase inhibitors (MMPIs) from marine natural products: the current situation and future prospects |
| Q38237471 | Matrix metalloproteinase inhibitors: a patent review (2011 - 2013). |
| Q37150788 | Matrix metalloproteinase-12 deficiency worsens relapsing-remitting experimental autoimmune encephalomyelitis in association with cytokine and chemokine dysregulation |
| Q37239871 | Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. |
| Q24299490 | Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain |
| Q37264609 | Matrix metalloproteinases 2 and 9 are differentially expressed in patients with indeterminate and cardiac clinical forms of Chagas disease |
| Q37375110 | Matrix metalloproteinases and their multiple roles in neurodegenerative diseases |
| Q47875381 | Matrix metalloproteinases and their tissue inhibitors (TIMPs) in Plasmodium falciparum malaria: serum levels of TIMP-1 are associated with disease severity |
| Q37444400 | Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock |
| Q36644577 | Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins |
| Q37242419 | Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9. |
| Q50184676 | Matrix metalloproteinases in emphysema. |
| Q28080664 | Matrix metalloproteinases in inflammatory bowel disease: an update |
| Q36210614 | Matrix metalloproteinases in neuropathic pain and migraine: friends, enemies, and therapeutic targets |
| Q34199345 | Matrix metalloproteinases in tumorigenesis: an evolving paradigm. |
| Q39162423 | Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy |
| Q38151704 | Matrix metalloproteinases, new insights into the understanding of neurodegenerative disorders |
| Q37308645 | Matrix metalloproteinases: drug targets for myocardial infarction |
| Q40830357 | Mechanistic investigations of matrix metalloproteinase-8 inhibition by metal abstraction peptide |
| Q35586223 | Membrane type-1 matrix metalloproteinase (MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2 (MMP-2) in inflammatory breast cancer |
| Q39817857 | Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammation. |
| Q41899118 | Metalloproteases and tendinopathy |
| Q28512433 | Metalloproteinase MT5-MMP is an essential modulator of neuro-immune interactions in thermal pain stimulation |
| Q36219151 | Metalloproteinases and their inhibitors are influenced by inhalative glucocorticoid therapy in combination with environmental dust reduction in equine recurrent airway obstruction |
| Q33660754 | Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics |
| Q62515266 | Metal–ligand interactions in drug design |
| Q54952381 | Microbial production of novel sulphated alkaloids for drug discovery. |
| Q34035175 | Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways |
| Q44327938 | Minocycline suppresses experimental autoimmune encephalomyelitis by increasing tissue inhibitors of metalloproteinases |
| Q43137867 | Minocycline with aspirin: a therapeutic approach in the treatment of diabetic neuropathy. |
| Q50516083 | Mobilization of bone marrow cells by CSF3 protects mice from bleomycin-induced lung injury. |
| Q36059874 | Modeling Structural Coordination and Ligand Binding in Zinc Proteins with a Polarizable Potential |
| Q58865283 | Modulation of Brain Injury as a Target of Adjunctive Therapy in Bacterial Meningitis |
| Q41048038 | Monitoring proteolytic processing events by quantitative mass spectrometry. |
| Q52682069 | Monoclonal antibodies against metzincin targets. |
| Q28083906 | Multifaceted role of matrix metalloproteinases (MMPs) |
| Q88886710 | Multimodal Molecular Imaging Demonstrates Myeloperoxidase Regulation of Matrix Metalloproteinase Activity in Neuroinflammation |
| Q47775396 | Multiple molecular modelling studies on some derivatives and analogues of glutamic acid as matrix metalloproteinase-2 inhibitors. |
| Q46487703 | Natural antioxidant polyphenols on inflammation management: Anti-glycation activity vs metalloproteinases inhibition |
| Q39517254 | Natural haemozoin modulates matrix metalloproteinases and induces morphological changes in human microvascular endothelium |
| Q35378782 | Neu1 sialidase and matrix metalloproteinase-9 cross-talk is essential for Toll-like receptor activation and cellular signaling. |
| Q41968510 | Neural functions of matrix metalloproteinases: plasticity, neurogenesis, and disease |
| Q37037317 | Neuroimmunology of central nervous system viral infections: the cells, molecules and mechanisms involved. |
| Q37976564 | Neurological diseases in relation to the blood-brain barrier |
| Q38950036 | Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications. |
| Q50047875 | Neutrophils: a cornerstone of liver ischemia and reperfusion injury. |
| Q42239363 | New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. |
| Q35544060 | New strategies for targeting matrix metalloproteinases |
| Q37532557 | New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy |
| Q58802393 | Novel Arginine-containing Macrocyclic MMP Inhibitors: Synthesis, Tc-labeling, and Evaluation |
| Q41175771 | Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors |
| Q30986676 | Optimization of total protein and activity assays for the detection of MMP-12 in induced human sputum |
| Q84313370 | Orally active, antimetastatic, nontoxic diphenyl ether-derived carbamoylphosphonate matrix metalloproteinase inhibitors |
| Q35175749 | Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy |
| Q48098141 | Overcoming neurite-inhibitory chondroitin sulfate proteoglycans in the astrocyte matrix. |
| Q34490917 | PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) |
| Q30499011 | POVME: an algorithm for measuring binding-pocket volumes |
| Q36919032 | Peptide-based selective inhibitors of matrix metalloproteinase-mediated activities |
| Q37017515 | Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats |
| Q35252779 | Plasma matrix metalloproteinases in neonates having surgery for congenital heart disease |
| Q81654439 | Poly(ADP-ribose) polymerase mediates inflammation in a mouse model of contact hypersensitivity |
| Q45905073 | Potentiation of aspirin-induced cerebroprotection by minocycline: a therapeutic approach to attenuate exacerbation of transient focal cerebral ischaemia. |
| Q39005974 | Preparation and evaluation of the effect of Fe3 O4 @piroctone olamine magnetic nanoparticles on matrix metalloproteinase-2: a preliminary in vitro study. |
| Q38972238 | Pro-Inflammatory and Pro-Fibrogenic Effects of Ionic and Particulate Arsenide and Indium-Containing Semiconductor Materials in the Murine Lung. |
| Q33608536 | Progress in matrix metalloproteinase research |
| Q38850914 | Prospects for the therapeutic application of sulfated polysaccharides of brown algae in diseases of the cardiovascular system: review |
| Q43753094 | Protective role of bortezomib in steatotic liver ischemia/reperfusion injury through abrogation of MMP activation and YKL-40 expression. |
| Q38783636 | Pyridazinone: an attractive lead for anti-inflammatory and analgesic drug discovery |
| Q30039761 | Pyrone-Based Inhibitors of Metalloproteinase Types 2 and 3 May Work as Conformation-Selective Inhibitors |
| Q34144797 | Recombinant TIMP-1-GPI inhibits growth of fibrosarcoma and enhances tumor sensitivity to doxorubicin |
| Q39239228 | Regulation of intestinal permeability: The role of proteases |
| Q30530312 | Regulation of the basement membrane by epithelia generated forces |
| Q43483685 | Relationship between leukocyte kinetics and behavioral tests changes in the inflammatory process of hemorrhagic stroke recovery |
| Q35083186 | Relationship between vitreous levels of matrix metalloproteinases and vascular endothelial growth factor in proliferative diabetic retinopathy |
| Q35007289 | Reversal of West Nile virus-induced blood-brain barrier disruption and tight junction proteins degradation by matrix metalloproteinases inhibitor |
| Q49569343 | Role of DDX3 in the pathogenesis of inflammatory bowel disease. |
| Q38626384 | Role of Matrix Metalloproteinases in the Pathogenesis of Traumatic Brain Injury |
| Q36468930 | Role of matrix metalloproteinase-2 and -9 in the development of diabetic retinopathy |
| Q36713661 | Role of metabolic modulator Bet-CA in altering mitochondrial hyperpolarization to suppress cancer associated angiogenesis and metastasis |
| Q39959867 | Role of the hemopexin domain of matrix metalloproteinases in cell migration |
| Q88165814 | Salvianolic acid A attenuates ischemia reperfusion induced rat brain damage by protecting the blood brain barrier through MMP-9 inhibition and anti-inflammation |
| Q37629036 | Secreted Frizzled-related protein 2 as a target in antifibrotic therapeutic intervention |
| Q38095854 | Secreted proteases of Trypanosoma brucei gambiense: possible targets for sleeping sickness control? |
| Q39249230 | Seeking for Non-Zinc-Binding MMP-2 Inhibitors: Synthesis, Biological Evaluation and Molecular Modelling Studies. |
| Q92692565 | Selected TLR7/8 agonist and type I interferon (IFN-α) cooperatively redefine the microglia transcriptome |
| Q27306938 | Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer |
| Q34513677 | Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2). |
| Q35308826 | Selective water-soluble gelatinase inhibitor prodrugs. |
| Q42816439 | Self-Assembled Wound Dressings Silence MMP-9 and Improve Diabetic Wound Healing In Vivo |
| Q37714909 | Small molecules for bone diseases |
| Q39145232 | Spatial mismatch, non-additive binding energies and selectivity in supramolecular complexes. |
| Q38318458 | Spinal cord injury induced neuropathic pain: Molecular targets and therapeutic approaches |
| Q47241630 | Spine-on-a-chip: Human annulus fibrosus degeneration model for simulating the severity of intervertebral disc degeneration |
| Q39329438 | Synergic and antagonistic relationship between MMP-2 and MMP-9 with fibrosis and inflammation in Chagas' cardiomyopathy. |
| Q27727742 | Synthesis and in Vitro and in Vivo Evaluation of MMP-12 Selective Optical Probes |
| Q53744193 | Synthesis, Antiphospholipase A₂, Antiprotease, Antibacterial Evaluation and Molecular Docking Analysis of Certain Novel Hydrazones. |
| Q39573243 | Target-Activated Prodrugs (TAPs) for the Autoregulated Inhibition of MMP12. |
| Q36963155 | Targeting MMPs in acute and chronic neurological conditions |
| Q35760031 | Targeting Matrix Metalloproteinases in Cancer: Bringing New Life to Old Ideas |
| Q37849424 | Tetracyclines and pain |
| Q24338163 | The Anti-inflammatory Role of Endometase/Matrilysin-2 in Human Prostate Cancer Cells |
| Q30486745 | The Concise Guide to PHARMACOLOGY 2013/14: enzymes. |
| Q26773190 | The Function and Roles of ADAMTS-7 in Inflammatory Diseases |
| Q36079853 | The Influence of Differentially Expressed Tissue-Type Plasminogen Activator in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis. |
| Q37310730 | The Kazal motifs of RECK protein inhibit MMP-9 secretion and activity and reduce metastasis of lung cancer cells in vitro and in vivo |
| Q24309142 | The Rap80-BRCC36 de-ubiquitinating enzyme complex antagonizes RNF8-Ubc13-dependent ubiquitination events at DNA double strand breaks |
| Q92959736 | The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma |
| Q37589671 | The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). |
| Q34980526 | The dual role of thymidine phosphorylase in cancer development and chemotherapy |
| Q46860326 | The efficient expression of human fibroblast collagenase in Escherichia coli and the discovery of flavonoid inhibitors. |
| Q37358106 | The emerging roles of ADAMTS-7 and ADAMTS-12 matrix metalloproteinases. |
| Q38014071 | The gelatinases and their inhibitors: the structure-activity relationships |
| Q28294058 | The impact of the extracellular matrix on inflammation |
| Q38881849 | The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases |
| Q42052538 | The role of manganese superoxide dismutase in skin aging |
| Q37693493 | The role of matrix metalloproteinases in colorectal cancer |
| Q38136195 | The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas |
| Q45337859 | The role of the macrophage in the development of aortic dissection |
| Q64940065 | Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer. |
| Q47371190 | Thrombin/Matrix Metalloproteinase-9-Dependent SK-N-SH Cell Migration is Mediated Through a PLC/PKC/MAPKs/NF-κB Cascade |
| Q37709748 | Towards a safe and effective chlamydial vaccine: lessons from the eye |
| Q39191612 | Towards integrating extracellular matrix and immunological pathways. |
| Q34607259 | Trachoma: protective and pathogenic ocular immune responses to Chlamydia trachomatis |
| Q37311960 | Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus |
| Q37029277 | Tuberculosis immunopathology: the neglected role of extracellular matrix destruction. |
| Q34132341 | Tumor necrosis factor-alpha augments matrix metalloproteinase-9 production in skeletal muscle cells through the activation of transforming growth factor-beta-activated kinase 1 (TAK1)-dependent signaling pathway |
| Q30449753 | Ultrasound enhanced matrix metalloproteinase-9 triggered release of contents from echogenic liposomes. |
| Q41544769 | Understanding the binding of inhibitors of matrix metalloproteinases by molecular docking, quantum mechanical calculations, molecular dynamics simulations, and a MMGBSA/MMBappl study |
| Q64275021 | Upregulated MMP28 in Hepatocellular Carcinoma Promotes Metastasis via Notch3 Signaling and Predicts Unfavorable Prognosis |
| Q42978654 | Upregulated expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in BALB/c mouse brain challenged with Japanese encephalitis virus |
| Q59136160 | Utility of Glycosylated TIMP3 molecules: Inhibition of MMPs and TACE to improve cardiac function in rat myocardial infarct model |
| Q30528882 | VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue |
| Q37138490 | Wasting mechanisms in muscular dystrophy. |
| Q34329995 | Zymography methods for visualizing hydrolytic enzymes. |
| Q42286935 | dCas9-mediated transcriptional activation of tissue inhibitor of metalloproteinases |
| Q42784361 | sFRP2 activates Wnt/β-catenin signaling in cardiac fibroblasts: differential roles in cell growth, energy metabolism, and extracellular matrix remodeling |
Search more.